Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Rectal Neoplasms 1Neoplasms 1Locally Advanced Solid Tumor 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 27pembrolizumab 21Brachytherapy 16Radiotherapy 14Carboplatin 10Radiation 8Paclitaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Topotecan 6fludarabine 5atezolizumab 5Magnetic Resonance Spectroscopy 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Nivolumab 4Gemcitabine 4tremelimumab 3temsirolimus 3human papillomavirus vaccine, L1 type 16, 18 3aldesleukin 3Radiotherapy, Intensity-Modulated 3Papillomavirus Vaccines 3Ipilimumab 3Interleukin-2 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Docetaxel 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uterine Cervical Neoplasms × E7046 × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡